These are our visions
•
0 likes•138 views
Visio digitaalisesta tulevaisuudesta – miten eri tietojärjestelmähankkeet tulevat näkymään yritysten, viranomaisten ja potilaiden arjessa.
Report
Share
Report
Share
Download to read offline
Recommended
Turun tyttöjen talo: Missä ne tytöt on? Työkaluja maahanmuuttajataustaisten t...
Turun tyttöjen talo: Missä ne tytöt on? Työkaluja maahanmuuttajataustaisten t...Lastensuojelun Keskusliitto
Elina Sinivaaran ja Henna Koivusen esitys Lasten suojelun kesäpäivillä 2018. Käytännön keinoja saatavuushäiriöiden paikkaamiseen
Saatavuushäiriöiden paikkaamiskeinoja Pohjoismaissa
Availability of medicines in the EU
The document summarizes the results of a survey on medicine availability in Europe conducted with experts in May 2019. It finds that most European countries require companies to notify authorities and make public notifications when medicines are out of stock. Most countries allow for a temporary "soft launch" period when implementing serialization requirements to avoid penalties for technical issues. The top challenges with serialization implementation have been systems not being connected to databases and issues uploading data. Countries provide waivers to serialization rules in cases like packaging changes to avoid stock-outs.
Artworkien aikarajat - osatekijä saatavuushäiriöissä?
Painettavien pakkausmateriaalien muutoshallinta
Mihin artworkien regulatoriset aikarajat perustuvat?
Mitä implementointi tarkoittaa?
VAJ-päivä: Kokemuksia viranomaistarkastuksista
Mitä pitää sisällään Fimean GDP-tarkastus? Valmistautuminen ja mitä tarkistetaan.
Pharmaceutical process validation
Process validation incorporates a lifecycle approach linking product and process development, validation of the commercial manufacturing process and maintenance of the process in a state of control during routine commercial production.
Excipients and GMP
Role and requirements of excipients in pharmaceuticals. Summary of new EU guideline published in March 2015 concerning risk assessment of excipients and excipient manufacturers.
Recommended
Turun tyttöjen talo: Missä ne tytöt on? Työkaluja maahanmuuttajataustaisten t...
Turun tyttöjen talo: Missä ne tytöt on? Työkaluja maahanmuuttajataustaisten t...Lastensuojelun Keskusliitto
Elina Sinivaaran ja Henna Koivusen esitys Lasten suojelun kesäpäivillä 2018. Käytännön keinoja saatavuushäiriöiden paikkaamiseen
Saatavuushäiriöiden paikkaamiskeinoja Pohjoismaissa
Availability of medicines in the EU
The document summarizes the results of a survey on medicine availability in Europe conducted with experts in May 2019. It finds that most European countries require companies to notify authorities and make public notifications when medicines are out of stock. Most countries allow for a temporary "soft launch" period when implementing serialization requirements to avoid penalties for technical issues. The top challenges with serialization implementation have been systems not being connected to databases and issues uploading data. Countries provide waivers to serialization rules in cases like packaging changes to avoid stock-outs.
Artworkien aikarajat - osatekijä saatavuushäiriöissä?
Painettavien pakkausmateriaalien muutoshallinta
Mihin artworkien regulatoriset aikarajat perustuvat?
Mitä implementointi tarkoittaa?
VAJ-päivä: Kokemuksia viranomaistarkastuksista
Mitä pitää sisällään Fimean GDP-tarkastus? Valmistautuminen ja mitä tarkistetaan.
Pharmaceutical process validation
Process validation incorporates a lifecycle approach linking product and process development, validation of the commercial manufacturing process and maintenance of the process in a state of control during routine commercial production.
Excipients and GMP
Role and requirements of excipients in pharmaceuticals. Summary of new EU guideline published in March 2015 concerning risk assessment of excipients and excipient manufacturers.
Introduction to biological active substances
Do you need consultation on the classification of biological active substances? Are you familiar with the documentation requirements? Do you need help in writing the documentation?
Lääketurvaan liittyvät muutoshakemukset ja sovittelumenettelyt käytännössä
Mitä referral-menettelyt ovat? PSUR-muutokset. PRAC-muutokset. Haittavaikutusraportointikehotukset
Vaj koulutus 25.9.2014 toimittajasopimukset-vastuunalaisuus
vastuunalaisen johtajan ajankohtaispäivä, toimittajasopimukset
Drug regulatory news 03 2014
The document summarizes drug regulatory news from March 2014. It discusses new EMA fees for pharmacovigilance activities that will significantly impact pharmaceutical companies. It also outlines several ongoing safety reviews by the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) of various drugs like codeine-containing medicines, testosterone medicines, and medicines acting on the renin-angiotensin system. National regulatory authorities like Fimea are updating terms for modified-release pharmaceutical forms.
Translations and-promotional-materials[1]
DRA Consulting’s medical translators combine their pharmacological expertise and knowledge of the
regulations and templates with fluent language skills.
Eregulatory intelligence[1]
Our specialists provide expertise in regulatory intelligence and strategic eRegulatory planning to help clients successfully manage their product lifecycles. We assist clients from the early preparation phase in publishing applications in eCTD/NeeS format and planning long-term eRegulatory strategies. In addition, we help with submissions to databases like EudraVigilance and can advise on registration and submission processes.
Regulatory intelligence[1]
DRA Consulting provides marketing authorization and market access services for medicinal products throughout their lifecycle from documentation preparation to product launch and maintenance. They offer to act as a company's Nordic regulatory department through outsourced services providing additional expertise, capacity, and flexibility so clients can focus on their core business. DRA Consulting has special expertise covering regulatory affairs for pharmaceutical and biotechnology companies.
More Related Content
More from DRA Consulting Oy
Introduction to biological active substances
Do you need consultation on the classification of biological active substances? Are you familiar with the documentation requirements? Do you need help in writing the documentation?
Lääketurvaan liittyvät muutoshakemukset ja sovittelumenettelyt käytännössä
Mitä referral-menettelyt ovat? PSUR-muutokset. PRAC-muutokset. Haittavaikutusraportointikehotukset
Vaj koulutus 25.9.2014 toimittajasopimukset-vastuunalaisuus
vastuunalaisen johtajan ajankohtaispäivä, toimittajasopimukset
Drug regulatory news 03 2014
The document summarizes drug regulatory news from March 2014. It discusses new EMA fees for pharmacovigilance activities that will significantly impact pharmaceutical companies. It also outlines several ongoing safety reviews by the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) of various drugs like codeine-containing medicines, testosterone medicines, and medicines acting on the renin-angiotensin system. National regulatory authorities like Fimea are updating terms for modified-release pharmaceutical forms.
Translations and-promotional-materials[1]
DRA Consulting’s medical translators combine their pharmacological expertise and knowledge of the
regulations and templates with fluent language skills.
Eregulatory intelligence[1]
Our specialists provide expertise in regulatory intelligence and strategic eRegulatory planning to help clients successfully manage their product lifecycles. We assist clients from the early preparation phase in publishing applications in eCTD/NeeS format and planning long-term eRegulatory strategies. In addition, we help with submissions to databases like EudraVigilance and can advise on registration and submission processes.
Regulatory intelligence[1]
DRA Consulting provides marketing authorization and market access services for medicinal products throughout their lifecycle from documentation preparation to product launch and maintenance. They offer to act as a company's Nordic regulatory department through outsourced services providing additional expertise, capacity, and flexibility so clients can focus on their core business. DRA Consulting has special expertise covering regulatory affairs for pharmaceutical and biotechnology companies.
More from DRA Consulting Oy (10)
Lääketurvaan liittyvät muutoshakemukset ja sovittelumenettelyt käytännössä
Lääketurvaan liittyvät muutoshakemukset ja sovittelumenettelyt käytännössä
Vaj koulutus 25.9.2014 toimittajasopimukset-vastuunalaisuus
Vaj koulutus 25.9.2014 toimittajasopimukset-vastuunalaisuus
Myyntilupaprosessit sujuviksi: MRP DCP prosessien käynnistäminen 11 2013
Myyntilupaprosessit sujuviksi: MRP DCP prosessien käynnistäminen 11 2013